In conclusion, this study, utilizing a comprehensive evidence-based approach through the LMBP framework, determines that HE4 is the most reliable serum biomarker for the early detection of NSCLC and the leading candidate for routine clinical use. This evidence concerns the gene WFDC2 and non-small cell lung carcinoma.